Application of general inula helenium sesquiterpene lactone in preparation of medicine for treating rheumatoid arthritis

Abstract

The invention provides application of general inula helenium sesquiterpene lactone in preparation of a medicine for treating rheumatoid arthritis. The general inula helenium sesquiterpene lactone contains alantolactone and isoalantolactone; and the sum of the contents of the alantolactone and the isoalantolactone accounts for 60 to 90%. The results of animal pharmacodynamic tests show that the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can inhibit the clinical onset of CIA (Collagen-induced Arthritis), obviously inhibit the morbidity of CIA, obviously reduce the level of IFN(Interferon)-gamma, and remarkably inhibit the generation of IL(Interleukin)-17. Therefore, the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can be used for preparing the medicine for treating rheumatoid arthritis. The medicine is composed of the general inula helenium sesquiterpene lactone serving as an active ingredient and a pharmaceutic adjuvant and can be in form of a troche, a capsule, a soft capsule, a dropping pill, granules, an injection, a powder-injection or an aerosol and the like. The medicine provided by the invention is a new medicine for treating rheumatoid arthritis, which has remarkable curative effect and little side reaction; the raw materials are conveniently obtained, the preparation method is simple, and the medicine has relatively high clinical application value.

Description

technical field [0001] The invention relates to medicines, in particular to the application of inulin total sesquiterpene lactones prepared from the traditional Chinese medicine Inula inula genus inulin in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease disease. The disease is prone to occur in small joints such as hands, wrists, and feet, and is easy to recur, and is symmetrically distributed. In the early stage of the disease, joints are red, swollen, hot, painful, and dysfunctional. In the late stage, the joints may appear stiff and deformed in varying degrees, accompanied by atrophy of bones and skeletal muscles, and are easily disabled. From the perspective of pathological ch...

AI Technical Summary

Problems solved by technology

2. Bedard PA, Golds EE: Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 1993, 154: 433-441) Increased IL-15 in rheumatoid arthritis models can be induced IL-17 exerts its pro-inflammatory cytokine properties, and IL-15 may lead to excessive secretion of IL-17 in joints through cyclosporin A and steroid-sensitive pathways

Images